63 related articles for article (PubMed ID: 8212641)
1. [The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies].
Cetkovský P; Koza V; Cepelák V; Vít L
Vnitr Lek; 1993 Sep; 39(9):871-5. PubMed ID: 8212641
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
3. The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients.
Yilmaz M; Dagdas S; Aki SZ; Guler N; Akoz AG; Erdin Z; Alanoglu G; Ozet G
Clin Lab Haematol; 2006 Oct; 28(5):313-6. PubMed ID: 16999721
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Scherrer A; Kruithof EK; Grob JP
Leukemia; 1991 Jun; 5(6):479-86. PubMed ID: 2056772
[TBL] [Abstract][Full Text] [Related]
5. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
6. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.
Moniwa N
Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654
[TBL] [Abstract][Full Text] [Related]
7. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
8. [Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance].
Shimmyozu K; Machigashira N; Itoyama T; Tara M; Maruyama I; Osame M
Rinsho Ketsueki; 1991 Feb; 32(2):173-5. PubMed ID: 2027244
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
11. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
Wang W; Ji CY; Ye JJ; Zhu YY; Guo DM; Ji M
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
[TBL] [Abstract][Full Text] [Related]
12. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
13. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Song KS; Lee A; Choi JR; Kwon OH
Thromb Haemost; 1995 Sep; 74(3):864-7. PubMed ID: 8571313
[TBL] [Abstract][Full Text] [Related]
16. [Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus].
Galajda P; Martinka E; Baláz D; Stasko J; Kerný J; Planková E; Mokán M; Kubisz P
Vnitr Lek; 1997 Nov; 43(11):744-7. PubMed ID: 9650506
[TBL] [Abstract][Full Text] [Related]
17. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients.
Haj MA; Robbie LA; Adey GD; Bennett B
Thromb Haemost; 1995 Dec; 74(6):1528-32. PubMed ID: 8772232
[TBL] [Abstract][Full Text] [Related]
19. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
[TBL] [Abstract][Full Text] [Related]
20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
